Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Head & Neck 2Gastrointestinal 2Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Colorectal Neoplasms 29Carcinoma, Non-Small-Cell Lung 17Pancreatic Neoplasms 12Neoplasm Metastasis 9Stomach Neoplasms 7Lung Neoplasms 7Rectal Neoplasms 6Neoplasms 6Melanoma 6Esophageal Neoplasms 6Colonic Neoplasms 6Ovarian Neoplasms 4Gastrointestinal Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Liver Neoplasms 2Hypopharyngeal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Biliary Tract Neoplasms 2Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Diseases 1

Interventions

Irinotecan 4Gemcitabine 4130-nm albumin-bound paclitaxel 4napabucasin 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3selpercatinib 2pembrolizumab 2cobimetinib 2Sunitinib 2Sorafenib 2Pemetrexed 2Paclitaxel 2Leucovorin 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Cetuximab 2Aspirin 2Ascorbic Acid 2trametinib 1repotrectinib 1pralsetinib 1osimertinib 1lutetium Lu 177 dotatate 1linifanib 1guadecitabine 1golotimod 1genexol-PM 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × Pemetrexed × Gastrointestinal × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡